Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
NCT03530683 · Pfizer · PHASE1 · terminated · last registry update 2024-09-03 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.” | Open Targets' class: business administrative | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-08-20Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Daunorubicin/Idarubicin + Cytarabine (NCT07132684)
- 2025-08-20Results posted on the registry: AbbVie, Venetoclax + Azacitidine (NCT04102020)
- 2025-06-05Phase 3 first posted: Kura Oncology, Inc., Ziftomenib + Placebo (NCT07007312)
- 2025-03-13Results posted on the registry: National Cancer Institute (NCI), Azacitidine + Pembrolizumab (NCT04284787)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-22Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Revumenib + Placebo (NCT06652438)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT06073730)
- 2023-09-18Results posted on the registry: Takeda, Pevonedistat + Venetoclax (NCT04266795)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision